STOCK TITAN

Mediwound - MDWD STOCK NEWS

Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.

MediWound Ltd (Nasdaq: MDWD) is a biopharmaceutical innovator developing enzymatic therapeutics for non-surgical wound care. This page provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic developments.

Access consolidated information about NexoBrid adoption, EscharEx clinical trials, and pipeline progress. Stay informed about financial results, partnership announcements, and market expansion initiatives directly impacting MediWound's position in wound care innovation.

Key updates include FDA/EMA regulatory decisions, burn treatment protocols, chronic wound therapy breakthroughs, and peer-reviewed research findings. All content is verified through primary sources to ensure accuracy for investment and clinical decision-making.

Bookmark this page for streamlined access to MediWound's latest developments. Combine our updates with SEC filings and earnings call transcripts for comprehensive analysis of this enzymatic therapeutics leader.

Rhea-AI Summary

MediWound Ltd. (Nasdaq: MDWD) announced patient enrollment in a phase 2 pharmacology study for EscharEx, an innovative enzymatic agent for chronic wound treatment. The trial will assess its effectiveness in debridement for lower leg ulcers with results anticipated in the second half of 2021. This study aims to evaluate safety and clinical performance, focusing on biofilm and inflammation impact. CEO Sharon Malka emphasized EscharEx's potential to improve chronic wound management, having shown positive safety and efficacy in prior trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
-
Rhea-AI Summary

MediWound Ltd. (Nasdaq: MDWD) announced an upcoming analyst day webinar on March 30, 2021, to highlight EscharEx, its enzymatic agent for chronic wound debridement. Esteemed experts will discuss U.S. chronic wound care practices and EscharEx's potential impact. The product showed promising results in Phase 2 studies, demonstrating safety and a higher incidence of complete debridement compared to hydrogel vehicles. The company’s existing product, NexoBrid, is under FDA evaluation, with a decision expected by June 29, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

MediWound Ltd. (Nasdaq: MDWD) has announced its participation in two upcoming virtual investor conferences in March 2021. The company will present at the Cowen 41st Annual Health Care Conference on March 2 at 9:10 am ET, and at the Oppenheimer 31st Annual Healthcare Conference on March 16 at 1:10 pm ET. Investors can access live webcasts of both events on the company's website, along with replays available for 30 days. MediWound focuses on innovative bio-therapeutic solutions for tissue repair, highlighted by its product NexoBrid, currently marketed in the EU and a BLA submitted for the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
conferences
Rhea-AI Summary

MediWound Ltd. (MDWD) reported a strong financial performance for Q4 and full-year 2020. Q4 revenues surged 23% to $6.7 million, fueled by BARDA's emergency stockpile procurement. Full-year revenues totaled $21.8 million, with product revenues up 117% to $7.8 million. The company achieved a gross margin from product sales of 60% for the full year. MediWound's cash and short-term investments totaled $21.6 million as of December 31, 2020. The FDA has accepted the Biologics License Application for NexoBrid, with a target review date set for June 29, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.54%
Tags
-
Rhea-AI Summary

MediWound Ltd. (MDWD) announced the initiation of a phase I/II clinical study for MWPC005 aimed at treating basal cell carcinoma (BCC). The study is set to begin in the second quarter of 2021, with results expected by the end of the year. MWPC005, utilizing bromelain, aims for non-invasive treatment without the side effects of current therapies. BCC is the most common skin cancer in the U.S., with approximately 4.3 million cases diagnosed annually. The clinical program includes trials in the U.S. and Israel, focusing on safety, tolerability, and preliminary efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.63%
Tags
-
Rhea-AI Summary

MediWound Ltd. (Nasdaq: MDWD) will release its financial results for Q4 and the year ended December 31, 2020, on February 25, 2021, at 7:00 am ET. This will be followed by a conference call at 8:30 am ET for management to discuss results and address questions. MediWound is a biopharmaceutical company focused on innovative therapies for severe burns and chronic wounds. Its products, NexoBrid and EscharEx, utilize patented enzyme technology for effective treatment. NexoBrid has been authorized in various countries, while EscharEx is currently under a U.S. phase 2 study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
conferences earnings
Rhea-AI Summary

MediWound Ltd. (Nasdaq: MDWD) announced that CEO Sharon Malka will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021, at 11:30 am ET. The event will be live-streamed on the company's website. MediWound specializes in innovative therapies for severe burn and wound management, notably its products NexoBrid and EscharEx, which utilize patented proteolytic enzyme technology. NexoBrid has received multiple market authorizations, including from the European Medicines Agency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
conferences
-
Rhea-AI Summary

MediWound Ltd. (Nasdaq: MDWD) has updated its EscharEx clinical development program, reducing the Phase 2 adaptive design study sample size to 120 patients due to COVID-19 related delays. This adjustment follows positive results from prior studies. The interim assessment is expected mid-2021 with complete enrollment by year-end 2021. Additionally, a protocol for a pharmacological study has been submitted to the FDA, with data anticipated in the second half of 2021. The company is optimistic about EscharEx's potential in chronic wound management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.15%
Tags
-
Rhea-AI Summary

MediWound Ltd. (Nasdaq: MDWD) announced its participation in the upcoming LifeSci Partners 10th Annual Corporate Access Event and the H.C. Wainwright BioConnect 2021 Conference, both held virtually. The LifeSci event will occur from January 6-8 and January 11-14, offering virtual 1x1 meetings with institutional investors. The BioConnect conference will take place from January 11-14, with a corporate update session available on-demand starting January 11 at 6:00 am (EST). MediWound focuses on innovative therapies for severe burns and chronic wounds, with products like NexoBrid and EscharEx.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.84%
Tags
conferences
Rhea-AI Summary

MediWound Ltd. (Nasdaq: MDWD) announced the successful completion of a pre-clinical study evaluating EscharEx, an innovative enzymatic debridement agent, against a commercially available collagenase agent. The study, conducted using a porcine model, showed that EscharEx outperformed the collagenase agent in removing eschars. Results will be published in a peer-reviewed journal in the first half of 2021. The company continues to advance its U.S. Phase 2 study for EscharEx, which has shown promising safety and efficacy in treating chronic wounds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
none
Mediwound

Nasdaq:MDWD

MDWD Rankings

MDWD Stock Data

184.81M
7.99M
19.75%
47.68%
8.65%
Biotechnology
Healthcare
Link
Israel
Yavne